Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Seres Therapeutics (MCRB) Net Margin: 2016-2025

Historic Net Margin for Seres Therapeutics (MCRB) over the last 8 years, with Sep 2025 value amounting to -6,227.64%.

  • Seres Therapeutics' Net Margin was N/A to -6,227.64% in Q3 2025 from the same period last year, while for Sep 2025 it was -39,168.22%, marking a year-over-year change of. This contributed to the annual value of 60.48% for FY2023, which is 356998.00% up from last year.
  • Per Seres Therapeutics' latest filing, its Net Margin stood at -6,227.64% for Q3 2025, which was down 195.90% from 6,494.01% recorded in Q1 2024.
  • Seres Therapeutics' 5-year Net Margin high stood at 6,494.01% for Q1 2024, and its period low was -13,634.87% during Q1 2023.
  • In the last 3 years, Seres Therapeutics' Net Margin had a median value of -4,216.88% in 2023 and averaged -4,290.42%.
  • As far as peak fluctuations go, Seres Therapeutics' Net Margin slumped by 984,223bps in 2023, and later skyrocketed by 2,012,888bps in 2024.
  • Over the past 5 years, Seres Therapeutics' Net Margin (Quarterly) stood at -692.44% in 2021, then crashed by 636,356bps to -7,056.00% in 2022, then crashed by 314,869bps to -10,204.69% in 2023, then surged by 2,012,888bps to 6,494.01% in 2024, then reached -6,227.64% in 2025.
  • Its Net Margin stands at -6,227.64% for Q3 2025, versus 6,494.01% for Q1 2024 and -10,204.69% for Q4 2023.